Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase Cγ2-protein kinase C-p38 MAPK cascade

Translational Research

Volumn 155, Issue 2, 2010, Pages 97-108

  Lin, Kuan H ^a   Chang, Yi F ^a   Fan, Chiao Y ^a   Jayakumar, Thanasekaran ^a   Lee, Jie J ^a   Chou, Duen S ^a   Hsiao, George ^a   Sheu, Joen Rong ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CALCIUM ION; COLLAGEN; HYDROXYL RADICAL; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE C; THROMBOXANE A2; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 74049137970     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.08.005     Document Type: Article

References (38)

1. Ohno R., Asou N., and Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17 (2003) 1454-1463
2. Parmar S., and Tallman M.S. Acute promyelocytic leukaemia:a review. Expert Opin Pharmacother 4 (2003) 1379-1392
3. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 62 (2002) 3893-3903
4. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
5. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 (2001) 3852-3860
6. Rojewski M.T., Baldus C., Knauf W., Thiel E., and Schrezenmeier H. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 116 (2002) 555-563
7. Kajiguchi T., Yamamoto K., Hossain K., et al. Sustained activation of c-jun terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 17 (2003) 2189-2195
8. Hayashi T., Hideshima T., Akiyama M., et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1 (2002) 851-860
9. Hyun Park W., Hee Cho Y., Won Jung C., et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 300 (2003) 230-235
10. Dai J., Weinberg R.S., Waxman S., and Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93 (1999) 268-277
11. Perkins C., Kim C.N., Fang G., and Bhalla K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95 (2000) 1014-1022
12. La Rosee P., Johnson K., O'Dwyer M.E., and Druker B.J. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30 (2002) 729-737
13. Sheu J.R., Lee C.R., Lin C.H., et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. Thromb Haemost 83 (2000) 777-784
14. Zhao W., Wang X., Guo W., et al. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J 133 (2000) 236-240
15. Sheu J.R., Hung W.C., Wu C.H., et al. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. Circulation 99 (1999) 3056-3062
16. Grynkiewicz G., Poenie M., and Tsien R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260 (1985) 3440-3450
17. Chou D.S., Hsiao G., Shen M.Y., Tsai Y.J., Chen T.F., and Sheu J.R. ESR spin trapping of a carbon-centered free radical from agonist-stimulated human platelets. Free Radic Biol Med 39 (2005) 237-248
18. Singer W.D., Brown H.A., and Sternweis P.C. Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Ann Rev Biochem 66 (1997) 475-509
19. Raffoux E., Rousselot P., Poupon J., et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21 (2003) 2326-2334
20. Amadori S., Fenaux P., Ludwig H., O'Dwyer M., and Sanz M. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 21 (2005) 403-411
21. Sheu J.R., Lin C.H., Peng H.C., and Huang T.F. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells. Proc Soc Exp Biol Med 213 (1996) 71-79
22. Mangin P., Yuan Y., Goncalves I., et al. Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA. J Biol Chem 278 (2003) 32880-32891
23. Pascale A., Amadio M., Govoni S., and Battaini F. The aging brain, a key target for the future: the protein kinase C involvement. Pharmacol Res 55 (2007) 560-569
24. Bunney T.D., and Katan M. Phospholipase C epsilon: linking second messengers and small GTPases. Trends Cell Biol 16 (2006) 640-648
25. Ragab A., Severin S., Gratacap M.P., et al. Roles of the C-terminal tyrosine residues of LAT in GPVI-induced platelet activation: insights into the mechanism of PLC gamma 2 activation. Blood 110 (2007) 2466-2474
26. Bugaud F., Nadal-Wollbold F., Levy-Toledano S., Rosa J.P., and Bryckaert M. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 94 (1999) 3800-3805
27. Hughes P.E., Renshaw M.W., Pfaff M., et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88 (1997) 521-530
28. Saklatvala J., Rawlinson L., Waller R.J., et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem 271 (1996) 6586-6589
29. Coulon L., Calzada C., Moulin P., Vericel E., and Lagarde M. Activation of p38 mitogen-activated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets. Free Radic Biol Med 35 (2003) 616-625
30. Tanaka Y., Gavrielides M.V., Mitsuuchi Y., Fujii T., and Kazanietz M.G. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278 (2003) 33753-33762
31. Ravi D., Muniyappa H., and Das K.C. Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism. Mol Cell Biochem 308 (2008) 193-200
32. Wachowicz B., Olas B., Zbikowska H.M., and Buczynski A. Generation of reactive oxygen species in blood platelets. Platelets 13 (2002) 175-182
33. Caccese D., Pratico D., Ghiselli A., et al. Superoxide anion and hydroxyl radical release by collagen-induced platelet aggregation-role of arachidonic acid metabolism. Thromb Haemost 83 (2000) 485-490
34. Leo R., Ghiselli A., Iuliano L., and Violi F. Detection of hydroxyl radicals by the salicylate bis-hydroxylation during arachidonic acid-dependent platelet activation. Thromb Haemost 73 (1995) A347
35. Au W.Y., Chim C.S., Lie A.K.W., Liang R., and Kwong Y.L. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 117 (2002) 130-132
36. Evens A.M., Tallman M.S., and Gartenhaus R.B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leukemia Res 28 (2004) 891-900
37. Barbey J.T., Pezzullo J.C., and Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21 (2003) 3609-3615
38. Soignet S.L., Maslak P., Wang Z.G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339 (1998) 1341-1348